CME 
JOBS 
OUTBREAKS 
PEER-TO-PEER 
QUIZZES & QUESTIONS 
MEDTECH With two cycles of neoadjuvant immunotherapy, nearly every patient with mismatch repair-deficient (dMMR) colon cancer in the NICHE-2 trial achieved a pathologic response. At a median follow-up of 13.1 months, the disease-free survival (DFS) rate was 100% vs. an expected rate for this patient population of 15%.
Peer-influenced content. Sources you trust. No registration required. This is HCN.
